John H. Strickler
Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer.
Overview
John Strickler is a gastrointestinal medical oncologist at Duke Cancer Institute. He was first author of the 2023 Lancet Oncology report of MOUNTAINEER, the phase 2 trial in which tucatinib plus trastuzumab produced durable responses in chemotherapy-refractory HER2-positive, RAS wild-type metastatic colorectal cancer, leading to accelerated approval. He also led early work on sotorasib in KRAS G12C colorectal cancer and studies ctDNA to guide therapy.
Similar pages
not linked directly; found by shared links- PersonAndrea Sartore-Bianchi
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonSalvatore Siena
Shares HER2-amplified colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonRona Yaeger
Shares Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonGerald W. Prager
Shares Colorectal cancer and the tags colorectal, trialist.
- PersonScott Kopetz
Shares Colorectal cancer and the tags colorectal, targeted-therapy.
- TrialTL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
- TrialMOUNTAINEER & MOUNTAINEER-03
Shares MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer, HER2-amplified colorectal cancer, Colorectal cancer.
- PersonAndrew J. Armstrong
Shares Duke Cancer Institute and the tag trialist.